Carlsbad, CA –January 22, 2007 - Next Pharmaceuticals announced today that it has signed an exclusive supply agreement with Kelatron for its patented Chromulin™ (U.S. Patent No. 6,689,383), an exciting breakthrough in chromium nutrition. Chromulin™ (chromium histidine) is water soluble and the most bio-available form of chromium, making it ideal for beverage applications and foods targeting any aspect of carbohydrate, protein, and fat metabolism.
“We are very pleased with the quality of Kelatron’s manufacturing and their excellent quality assurance and control,” said Bob Garrison, President & CEO of Next Pharmaceuticals. “We believe Chromulin™ will rise rapidly to be the number one choice for chromium and that new and exciting applications in weight control, blood sugar control, and cardiovascular health will come out of our research this year.”
Chromulin™ is a natural combination of the essential mineral Chromium III with the essential amino acid histidine, formulated and patented by Dr. Richard A. Anderson at the US Department of Agriculture and licensed to Next Pharmaceuticals. This formulation is stable, has better absorption and is safer than other forms of chromium.
About Kelatron Corporation
Kelatron manufactures and markets mineral nutrients worldwide to the nutritional supplement, nutraceutical and health food segment. Founded over 25 years ago, Kelatron has developed the reputation as a world leader in mineral nutrition. All products are produced under exact specification and are laboratory tested. For more information log onto www.kelatroncorp.com.
About Next Pharmaceuticals
Next Pharmaceuticals (NP) was founded in 1997 with the purpose of developing new, patented, natural ingredients for healthy living products in the dietary supplement, food and beverage industries. The goal of the company is to expand self-care and keep people out of the health care system for a longer period of time. NP has successfully developed seven ingredients that have significantly expanded the choices for self-care products while providing large consumer brands with powerful product differentiation. For more information log onto www.nextpharmaceuticals.com. For all media inquiries, please contact Connie St. John at 415-454-2243 or 415-302-7438 mobile.
# # #